Exelixis Beheer

Beheer criteriumcontroles 3/4

De CEO Exelixis is Mike Morrissey, benoemd in Jul2010, heeft een ambtstermijn van 14.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 16.42M, bestaande uit 7.3% salaris en 92.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.56% van de aandelen van het bedrijf, ter waarde € 55.83M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.5 jaar en 7.4 jaar.

Belangrijke informatie

Mike Morrissey

Algemeen directeur

US$16.4m

Totale compensatie

Percentage CEO-salaris	7.3%
Dienstverband CEO	14.3yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	8.5yrs
Gemiddelde ambtstermijn bestuur	7.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Mike Morrissey's beloning veranderd ten opzichte van Exelixis's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$467m
Jun 30 2024	n/a	n/a	US$350m
Mar 31 2024	n/a	n/a	US$205m
Dec 31 2023	n/a	n/a	US$208m
Sep 30 2023	n/a	n/a	US$92m
Jun 30 2023	n/a	n/a	US$164m
Mar 31 2023	n/a	n/a	US$154m
Dec 31 2022	US$17m	US$1m	US$182m
Sep 30 2022	n/a	n/a	US$308m
Jun 30 2022	n/a	n/a	US$273m
Mar 31 2022	n/a	n/a	US$298m
Dec 31 2021	US$8m	US$1m	US$231m
Sep 30 2021	n/a	n/a	US$164m
Jun 30 2021	n/a	n/a	US$94m
Mar 31 2021	n/a	n/a	US$65m
Dec 31 2020	n/a	n/a	US$112m
Sep 30 2020	n/a	n/a	US$152m
Jun 30 2020	n/a	n/a	US$282m
Mar 31 2020	n/a	n/a	US$294m
Dec 31 2019	n/a	n/a	US$321m
Sep 30 2019	n/a	n/a	US$612m
Jun 30 2019	n/a	n/a	US$642m
Mar 31 2019	n/a	n/a	US$650m
Dec 31 2018	n/a	n/a	US$690m
Sep 30 2018	n/a	n/a	US$368m
Jun 30 2018	n/a	n/a	US$323m
Mar 31 2018	n/a	n/a	US$253m
Dec 31 2017	n/a	n/a	US$154m

Compensatie versus markt: De totale vergoeding ($USD 16.42M ) Mike } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 4.86M ).

Compensatie versus inkomsten: De vergoeding van Mike is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Mike Morrissey (63 yo)

14.3yrs

Tenure

US$16,423,307

Compensatie

Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Stelios Papadopoulos	Co-Founder & Chair of the Board	29.9yrs	US$519.97k	0.43% € 43.1m
Michael Morrissey	CEO, President & Director	14.3yrs	US$16.42m	0.56% € 55.8m
Christopher Senner	Executive VP & CFO	9.3yrs	US$4.95m	0.16% € 16.2m
Dana Aftab	Executive VP of Discovery and Translational Research & Chief Scientific Officer	1.9yrs	US$5.65m	0.080% € 7.9m
Jeffrey Hessekiel	Executive VP & General Counsel	10.8yrs	US$4.56m	0.11% € 10.8m
Amy Peterson	Executive VP	1.3yrs	US$7.38m	0.10% € 10.3m
Susan Hubbard	Executive Vice President of Public Affairs & Investor Relations	7.9yrs	geen gegevens	geen gegevens
Tony Redmond	Senior Vice President of Human Resources	less than a year	geen gegevens	geen gegevens
Anne Champsaur	Senior Vice President of Drug Safety	9.6yrs	geen gegevens	geen gegevens
William Berg	Senior Vice President of Medical Affairs	9.2yrs	geen gegevens	geen gegevens
Patrick Haley	Executive Vice President of Commercial	7.9yrs	US$4.65m	0.039% € 3.9m
Stefan Krauss	VP & Head of Business Development	no data	geen gegevens	geen gegevens

8.5yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EX9 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stelios Papadopoulos	Co-Founder & Chair of the Board	29.9yrs	US$519.97k	0.43% € 43.1m
Michael Morrissey	CEO, President & Director	14.3yrs	US$16.42m	0.56% € 55.8m
Jack Wyszomierski	Independent Director	20.8yrs	US$490.97k	0.12% € 11.5m
George Poste	Independent Director	20.3yrs	US$482.22k	0.053% € 5.2m
Charles Sawyers	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Ronald Evans	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Sue Eckhardt	Independent Director	less than a year	geen gegevens	0% € 0
Mary Beckerle	Independent Director	less than a year	geen gegevens	0% € 0
Julie Smith	Independent Director	8.2yrs	US$490.92k	0.00027% € 26.8k
Maria Freire	Independent Director	6.6yrs	US$488.72k	0.025% € 2.5m
Robert Oliver	Independent Director	1.5yrs	US$717.44k	0.0016% € 158.0k
Tomas Heyman	Independent Director	1.5yrs	US$716.19k	0.0016% € 158.0k

7.4yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EX9 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.4 jaar).

Exelixis Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Independent Director recently sold €940k worth of stock

Independent Director recently sold €831k worth of stock

Independent Director recently sold €531k worth of stock

Exelixis, Inc., Annual General Meeting, May 30, 2024

Executive Vice President of Commercial recently sold €932k worth of stock

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

Recent updates

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Independent Director recently sold €940k worth of stock

Investor sentiment improves as stock rises 23%

Exelixis, Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024

Exelixis, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Exelixis, Inc Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Independent Director recently sold €831k worth of stock

Exelixis, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors

Second quarter 2024 earnings released: EPS: US$0.78 (vs US$0.25 in 2Q 2023)

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $500 million worth of its shares.

Exelixis, Inc. Announces U.S. Food and Drug Administration Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors

Exelixis, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Independent Director recently sold €531k worth of stock

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

First quarter 2024 earnings released: EPS: US$0.12 (vs US$0.12 in 1Q 2023)

Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024

Exelixis, Inc., Annual General Meeting, May 30, 2024

Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Executive Vice President of Commercial recently sold €932k worth of stock

Full year 2023 earnings released: EPS: US$0.65 (vs US$0.57 in FY 2022)

Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024

Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022)

Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Exelixis, Inc. Elects Dave Johnson to its Board of Directors

First quarter 2023 earnings released: EPS: US$0.12 (vs US$0.21 in 1Q 2022)

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

Bristol-Myers Squibb Company and Exelixis, Inc. Announces Opdivo in Combination with Cabometyx Shows Durable Survival with over Three Years of Follow-Up in the Checkmate -9Er Trial in First-Line Advanced Renal Cell Carcinoma

Exelixis, Inc. and Sairopa B.V. Announces US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

Full year 2022 earnings released: EPS: US$0.57 (vs US$0.73 in FY 2021)

Exelixis, Inc. Provides Revenue Guidance for Fiscal Year 2023

Exelixis, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Exelixis, Inc. Provides Revenue Guidance for Full Year 2023

Exelixis, Inc. Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer

Exelixis, Inc. Announces Board Appointments

Exelixis, Inc. Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

Exelixis, Inc. Announces Initial Dose-Escalation Results from the First-In-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$0.23 (vs US$0.12 in 3Q 2021)

Exelixis, Inc. Provides Revenue Guidance for 2022

Exelixis, Inc. Announces Promising Initial Dose-Escalation Results from the First-In-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022

Exelixis, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Exelixis, Inc. Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

Exelixis, Inc. Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022

Second quarter 2022 earnings released: EPS: US$0.22 (vs US$0.31 in 2Q 2021)

Exelixis, Inc. Maintains Earnings Guidance for the Fiscal Year 2022

Exelixis, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Exelixis, Inc. Announces COSMIC-313 Met Its Primary Endpoint

Investor sentiment improved over the past week

Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer

Executive Vice President of Commercial recently sold €320k worth of stock

Exelixis, Inc. Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2022

First quarter 2022 earnings released: EPS: US$0.21 (vs US$0.005 in 1Q 2021)

Insufficient new directors

Exelixis, Inc. Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma

Exelixis, Inc. Announces Charles Cohen to Retire from Board of Directors

Co-Founder & Independent Chairman recently sold €1.5m worth of stock